A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder.

Background: Divalproex (DVP) and oxcarbazepine (OXC) are used to treat pediatric bipolar disorder (PBPD) with severe aggression but these agents have not been compared in head to head trials.

Methods: Electronic medical records were reviewed for those (age < 18) who received DVP (n = 20) or OXC (n = 11) for the treatment of PBPD with severe aggression. Change in prospectively rated Clinical Global Impressions-Severity (CGI-S) scores that measured global improvement of mental illness from baseline and rates of discontinuation due to adverse effects at approximately 4 months were the primary outcomes.

No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series.

Objective: The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders.

Method: We retrospectively reviewed the outpatient psychopharmacology medical records of patients with epilepsy, aged 19 and younger, who received risperidone for psychiatric disorders.

Results: Twenty-one (21) youths (mean age, 12.